当前位置: X-MOL 学术BBA Mol. Cell Biol. Lipids › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Promotion of plasmalogen biosynthesis reverse lipid changes in a Barth Syndrome cell model.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ( IF 4.8 ) Pub Date : 2020-02-29 , DOI: 10.1016/j.bbalip.2020.158677
José Carlos Bozelli 1 , Daniel Lu 2 , G Ekin Atilla-Gokcumen 2 , Richard M Epand 1
Affiliation  

In Barth syndrome (BTHS) mutations in tafazzin leads to changes in both the quantities and the molecular species of cardiolipin (CL), which are the hallmarks of BTHS. Contrary to the well-established alterations in CL associated with BTHS; recently a marked decrease in the plasmalogen levels in Barth specimens has been identified. To restore the plasmalogen levels, the present study reports the effect of promotion of plasmalogen biosynthesis on the lipidome of lymphoblasts derived from Barth patients as well as on cell viability, mitochondria biogenesis, and mitochondrial membrane potential. High resolution 31P NMR phospholipidomic analysis showed an increase in the levels of plasmenylethanolamine (the major plasmalogen in lymphoblasts), which reached values comparable to the control and a compensatory decrease in the levels of its diacyl-PE counterpart. Importantly, 31P NMR showed a significant increase in the levels of CL, while not altering the levels of monolysocardiolipin. Mass spectrometry measurements showed that the promotion of plasmalogen biosynthesis did not change the molecular species profile of targeted phospholipids. In addition, promotion of plasmalogen biosynthesis did not impact on cellular viability, although it significantly decrease mitochondria copy number and restored mitochondrial membrane potential. Overall, the results showed the efficacy of the promotion of plasmalogen biosynthesis on increasing the CL levels in a BTHS cell model and highlight the potential beneficial effect of a diet supplemented with plasmalogen precursors to BTHS patients.

中文翻译:

促进缩醛磷脂生物合成逆转Barth综合征细胞模型中的脂质变化。

在Barth综合征(BTHS)中,他夫嗪的突变会导致心磷脂(CL)的数量和分子种类发生变化,这是BTHS的标志。与BTHS相关的CL中公认的改变相反;最近,已经确定了Barth标本中缩醛磷脂水平的显着下降。为了恢复缩醛磷脂的水平,本研究报道了促进缩醛磷脂生物合成对来自Barth患者的淋巴母细胞脂质体以及细胞活力,线粒体生物发生和线粒体膜电位的影响。高分辨率31P NMR磷脂分析显示,血浆烯基乙醇胺(淋巴母细胞中的主要缩醛磷脂)水平增加,其值达到与对照相当的水平,并且其二酰基-PE对应物的水平下降。重要的是,31 P NMR显示CL的水平显着增加,而不会改变单溶心磷脂的水平。质谱测量表明,缩醛磷脂生物合成的促进并未改变靶向磷脂的分子种类分布。此外,促进缩醛缩醛生物合成虽然不会显着降低线粒体拷贝数并恢复了线粒体膜电位,但对细胞活力没有影响。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。重要的是,31 P NMR显示CL的水平显着增加,而不会改变单溶心磷脂的水平。质谱测量表明,缩醛磷脂生物合成的促进并未改变靶向磷脂的分子种类分布。此外,促进缩醛缩醛生物合成虽然不会显着降低线粒体拷贝数并恢复了线粒体膜电位,但对细胞活力没有影响。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。重要的是,31 P NMR显示CL的水平显着增加,而不会改变单溶心磷脂的水平。质谱测量表明,缩醛磷脂生物合成的促进并未改变靶向磷脂的分子种类分布。此外,促进缩醛缩醛生物合成虽然不会显着降低线粒体拷贝数并恢复了线粒体膜电位,但对细胞活力没有影响。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。质谱测量表明,缩醛磷脂生物合成的促进并未改变靶向磷脂的分子种类分布。此外,促进缩醛缩醛生物合成虽然不会显着降低线粒体拷贝数并恢复了线粒体膜电位,但对细胞活力没有影响。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。质谱测量表明,缩醛磷脂生物合成的促进并未改变靶向磷脂的分子种类分布。此外,促进缩醛缩醛生物合成虽然不会显着降低线粒体拷贝数并恢复了线粒体膜电位,但对细胞活力没有影响。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。尽管它显着降低了线粒体的拷贝数并恢复了线粒体膜电位。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。尽管它显着降低了线粒体的拷贝数并恢复了线粒体膜电位。总体而言,结果表明,在BTHS细胞模型中,促进缩醛缩醛生物合成提高CL水平的功效,并突出了补充缩醛缩醛前体饮食对BTHS患者的潜在有益作用。
更新日期:2020-03-02
down
wechat
bug